Myths and facts about the EARLYSTIM study

Area of Science:

• Neurology
• Neurosurgery
• Movement Disorders

Background:

• Subthalamic nucleus deep brain stimulation (STN-DBS) is effective for advanced Parkinson's disease (PD).
• The EARLYSTIM study demonstrated benefits of STN-DBS in PD patients with early motor complications.
• Recent debates question the EARLYSTIM study's findings, particularly regarding placebo effects.

Purpose of the Study:

• To argue against a significant placebo or "lessebo" effect contributing to STN-DBS outcomes in the EARLYSTIM study.
• To highlight methodological flaws in previous attempts to quantify DBS placebo effects.
• To discuss challenges and criteria for considering earlier STN-DBS in PD.

Main Methods:

• Critique of methodologies used to assess placebo effects in deep brain stimulation (DBS).
• Discussion of the practical impossibility of effective blinding in STN-DBS for Parkinson's disease.
• Analysis of potential challenges in early STN-DBS, including patient selection and multidisciplinary care needs.

Main Results:

• A significant placebo effect is unlikely to explain the positive outcomes observed in the EARLYSTIM study.
• Previous methods for quantifying DBS placebo effects are flawed, yielding implausible results.
• The extent of any placebo effect in STN-DBS for PD is likely minimal.

Conclusions:

• STN-DBS offers substantial benefits for quality of life and motor function in Parkinson's disease, even with early motor complications.
• The EARLYSTIM study's findings are robust and not significantly influenced by placebo effects.
• Earlier intervention with STN-DBS, upon onset of relevant disability from motor complications, can extend years of improved quality of life for PD patients.